Markers of coagulation activation for evaluation of the antithrombotic efficacy of heparin

Rm, Mesters; Mikoteit, Thorsten; Schiller, Medad; Krings, Wolfgang; Ostermann, Helmut; Kienast, J.

doi:10.1097/00001721-199510000-00007

Cited by 11 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,9,10 Although large human clinical outcome studies comparing aPTT with antifactor Xa or antifactor IIa have not been performed, there are reports showing better correlation of clinical outcomes with antifactor Xa assays than with aPTT. [11][12][13][14] An important rabbit thrombosis study showed that antifactor IIa levels were a more reliable predictor of antithrombotic effectiveness than were aPTT values. 15 The target antifactor Xa activity for UFH therapy is 0.3-0.7 U/ml as measured by a chromogenic amidolytic assay.…”

mentioning

confidence: 99%

Achieving Target Antifactor Xa Activity with a Heparin Protocol Based on Sex, Age, Height, and Weight

Rosborough

Shepherd

2004

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Achieving Target Antifactor Xa Activity with a Heparin Protocol Based on Sex, Age, Height, and Weight

Rosborough

Shepherd

2004

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…A reduced normalisation of D-dimers (24), D-dimer and TAT (25) and high TAT complexes and thrombin F1+2 coincided with a reduced response to treatment (17,26,27) in patients with acute DVT. In a small study F1+2 levels and TAT complexes as well as D-dimer failed to indicate DVT progression (28).…”

Section: Discussionmentioning

confidence: 88%

Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis

Breddin¹,

Kadziola²,

Scully³

et al. 2003

Thromb Haemost

View full text Add to dashboard Cite

SummaryPossible correlation of the effects of pharmacotherapy on the inhibition of the in-vivo generation of thrombin and on the prevention of thrombus extension in patients with deep vein thrombosis (DVT) could help to define patients at higher risk.Patients with symptomatic deep vein thrombosis confirmed by phlebography were randomised to intravenous unfractionated heparin (UFH), or a subcutaneous low-molecular-weight heparin (reviparin) twice daily for one week, or a subcutaneous reviparin once daily for four weeks. The patients were treated with oral anticoagulants for at least 3 months. Main endpoints were regression of thrombus on phlebography on Day 21 and recurrent symptomatic venous thromboembolism up to 3 months. Coagulation parameters, markers of in-vivo thrombin generation, and TFPI-release were determined at randomisation, weeks 1 and 3.Four hundred sixty six responders (reduction of at least 30 per cent in Marder score) and 419 non-responders (Marder score unchanged or changed less than ±30%) showed no significantly different baseline characteristics. The non-responder group had a higher median Marder score at baseline and after one and three weeks of treatment, and had significantly higher fibrinogen levels, TAT complexes and F1+2 values than responders. There were no significant differences in coagulation parameters between non-responders and patients with asymptomatic + symptomatic VTE with the exception of higher TAT complexes at baseline.Significant differences in Marder score and coagulation parameters at baseline were found between responders and non-responders. Non-responders have a higher risk tosuffer recurrent VTE and may need intensified treatment.

show abstract

“…Duplicates from these 2 searches were identified and discarded, leaving 4059 unique articles. Screening and study selection as described above resulted in the identification of 20 articles 20–39 meeting the inclusion criteria (Figure 1). Two articles 29,32 reported data found in other included reports 31,34 and were not included in the final analysis.…”

Section: Resultsmentioning

confidence: 99%

Thrombin Generation Biomarkers Decline With Parenteral Anticoagulation—An Overlooked Means of Anticoagulation Monitoring?

McFarland

Lind

2018

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Anticoagulation therapy is administered to patients to prevent or stop thrombin generation in vivo. Although plasma tests of in vivo thrombin generation have been available for more than 2 decades, they are not routinely used in clinical trials or practice to monitor anticoagulation therapy. We observed a fall in one such marker, the D-dimer antigen, in patients receiving anticoagulation therapy. We therefore conducted a systematic review of the medical literature to document the change in serum biomarkers of thrombin generation following the initiation of anticoagulation therapy. Using a defined search strategy, we screened PubMed and Embase citations and identified full-length articles published in English. Eighteen articles containing serial changes in 1 of 3 markers of thrombin generation (D-dimer antigen, thrombin-antithrombin complexes, and prothrombin fragment 1þ2 antigen levels) in the 14 days following the initiation of anticoagulation were identified. Even though the assays used varied considerably, each of the 3 markers of thrombin generation declined in the initial period of anticoagulation therapy, with changes evident as early as 1 day after beginning therapy. These observations provide a rationale for further exploration of these markers as measures of the adequacy of anticoagulation using classic as well as novel anticoagulants. Particular patient groups that would benefit from additional means of monitoring anticoagulation therapy are discussed.

show abstract

Markers of coagulation activation for evaluation of the antithrombotic efficacy of heparin

Cited by 11 publications

References 0 publications

Achieving Target Antifactor Xa Activity with a Heparin Protocol Based on Sex, Age, Height, and Weight

Achieving Target Antifactor Xa Activity with a Heparin Protocol Based on Sex, Age, Height, and Weight

Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis

Thrombin Generation Biomarkers Decline With Parenteral Anticoagulation—An Overlooked Means of Anticoagulation Monitoring?

Contact Info

Product

Resources

About